SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-056440
Filing Date
2021-11-12
Accepted
2021-11-12 07:00:49
Documents
17
Period of Report
2021-11-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tals-8k_20211112.htm   iXBRL 8-K 36680
2 EX-99.1 tals-ex991_6.htm EX-99.1 102636
3 GRAPHIC gp5n4pqagaed000004.jpg GRAPHIC 3469
4 GRAPHIC gp5n4pqagaed000002.jpg GRAPHIC 3469
5 GRAPHIC gp5n4pqagaed000003.jpg GRAPHIC 3469
6 GRAPHIC gp5n4pqagaed000001.jpg GRAPHIC 3469
  Complete submission text file 0001564590-21-056440.txt   298249

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA tals-20211112.xsd EX-101.SCH 5673
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE tals-20211112_lab.xml EX-101.LAB 19509
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tals-20211112_pre.xml EX-101.PRE 11478
10 EXTRACTED XBRL INSTANCE DOCUMENT tals-8k_20211112_htm.xml XML 3546
Mailing Address 201 E. JEFFERSON ST., SUITE 110B LOUISVILLE KY 40202
Business Address 201 E. JEFFERSON ST., SUITE 110B LOUISVILLE KY 40202 502-569-1059
Talaris Therapeutics, Inc. (Filer) CIK: 0001827506 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40384 | Film No.: 211399445
SIC: 2836 Biological Products, (No Diagnostic Substances)